Clorox (CLX)
NYSEConsumer StaplesHousehold & Personal ProductsSnapshot 2026-07-07
$97.42+0.17%
Close 2026-07-07 · 1-day change
Reading CLX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CLX free→NYSEConsumer StaplesHousehold & Personal ProductsSnapshot 2026-07-07
Reading CLX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CLX free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a turnaround story with a medium level of confidence. The company is facing challenges in sales and margins, but recent changes in management and a focus on integration could provide a path forward.
The current valuation suggests that the market sees CLX as relatively cheap compared to its peers, with a slight expectations gap. However, the market also reflects a low level of fragility due to weak execution quality.
Fundamentals are expected to remain neutral in the near term, as the company struggles with sales declines and margin pressures. Management is addressing these issues, but progress has been limited.
The long-term thesis hinges on the company's ability to improve guidance in the next quarter and the performance of sector leaders like PG and UL. Positive shifts in these areas could signal a recovery.
Overall, CLX is in a cautious position as it works through its challenges and sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Signal changed from 'mild_favorable' to 'mixed'.
Yes, our read has strengthened. The latest earnings beat supports this improvement, indicating a positive shift in financial performance. There are no new threats identified that could weaken this outlook.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Sales results will show if Clorox can reverse its sales decline. This is crucial for future growth.
Confirms:Q4 sales results show a decline worse than 6% year over year.
Disproves:Q4 sales results show a decline less than 6% year over year.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Gross margin trends impact how much money Clorox makes. Managing margin decline is key for its finances.
Confirms:Gross margin declines more than 300 basis points in Q4 compared to the previous year.
Disproves:Gross margin declines less than 250 basis points in Q4 compared to the previous year.
Why it matters: The new CEO will set the direction for Clorox's future growth. Leadership changes can impact investor confidence.
Confirms one read:An announcement confirming the appointment of a new CEO who has a strong track record in consumer goods.
Confirms the other:There is a long delay in choosing a new CEO. This creates uncertainty in leadership.
Why it matters: Successful integration can drive growth and enhance Clorox's product offerings. This is key for future performance.
Confirms:Public updates show that GOJO products are selling well. They are also being integrated successfully.
Disproves:There are no updates or bad news about integration and sales from GOJO.
Why it matters: Organic sales growth is important. It helps us see how Clorox is gaining market share.
Confirms one read:Organic sales are getting better. They fell less than the expected 9% from last year.
Confirms the other:Organic sales fell more than 9%. This shows ongoing market share problems.
Why it matters: Gross margin trends will indicate how well Clorox is managing costs amidst challenges.
Confirms:Gross margin remains above 43% despite cost pressures and shows signs of recovery.
Disproves:Gross margin is under 40%. This shows there are cost management problems.